For decades, life with sickle cell disease (SCD) was marked by a lack of treatment options. When people with the disease had a stroke or a debilitating pain episode — symptoms that combined to cut decades off their lives — doctors had little to offer besides pain medications. That might start to change in December, when federal officials could approve two cutting-edge gene therapies for SCD.
